Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program

Published:2019-06-20 Issue:12 Volume:145 Page:3359-3369
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Jacot William¹²^ORCID,Heudel Pierre‐Etienne³,Fraisse Julien¹,Gourgou Sophie¹,Guiu Séverine¹²,Dalenc Florence⁴,Pistilli Barbara⁵,Campone Mario⁶,Levy Christelle⁷,Debled Marc⁸,Leheurteur Marianne⁹,Chaix Marie¹⁰,Lefeuvre Claudia¹¹,Goncalves Anthony¹²,Uwer Lionel¹³,Ferrero Jean‐Marc¹⁴,Eymard Jean‐Christophe¹⁵,Petit Thierry¹⁶,Mouret‐Reynier Marie‐Ange¹⁷,Courtinard Coralie¹⁸,Cottu Paul¹⁹,Robain Mathieu¹⁸,Mailliez Audrey²⁰

Affiliation:

1. Institut du Cancer de Montpellier (ICM) Val d'AurelleMontpellier University Montpellier France

2. IRCM INSERM U1194 Montpellier France

3. Centre Léon Bérard Lyon France

4. Institut Claudius RegaudIUCT‐Oncopole Toulouse France

5. Gustave Roussy Villejuif France

6. Institut de Cancérologie de l'Ouest Saint‐Herblain France

7. Centre François‐Baclesse Caen France

8. Institut Bergonié Bordeaux France

9. Centre Henri Becquerel Rouen France

10. Centre Georges Francois Leclerc Dijon France

11. Centre Eugène Marquis Rennes France

12. Institut Paoli‐Calmettes Marseille France

13. Institut de Cancérologie de Lorraine Vandœuvre‐lès‐Nancy France

14. Centre Antoine Lacassagne Nice France

15. Institut de Cancérologie Jean Godinot Reims France

16. Centre Paul Strauss Strasbourg France

17. Centre Jean‐Perrin Clermont‐Ferrand France

18. UNICANCER Paris France

19. Etablissement Hospitalier Institut Curie Paris France

20. Centre Oscar Lambret Lille France

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32402

Reference30 articles.

1. Cancer statistics, 2018

2. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

3. Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

4. Review on the clinical use of eribulin mesylate for the treatment of breast cancer

5. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer;Clinical Breast Cancer;2024-06

2. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes;Cancer Medicine;2024-05

3. Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis;Cancer Medicine;2023-07-05

4. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database;BMC Medicine;2023-03-08

5. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study;Breast Cancer Research;2022-10-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3